Novavax Inc. Stock
Novavax Inc. Stock
The Novavax Inc. stock is trending slightly upwards today, with an increase of €0.040 (0.620%) compared to yesterday's price.
Currently there is a rather positive sentiment for Novavax Inc. with 9 Buy predictions and 3 Sell predictions.
As a result the target price of 11 € shows a very positive potential of 70.54% compared to the current price of 6.45 € for Novavax Inc..
For the coming years our community has positive and negative things to say abot the Novavax Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.
Pros and Cons of Novavax Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Novavax Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novavax Inc. | 0.620% | -7.637% | -21.829% | 5.549% | 11.034% | -13.890% | -95.857% |
| Evolus Inc | -0.500% | 4.547% | -13.717% | -32.481% | -2.128% | -41.385% | -42.022% |
| Heron Therapeutics Inc. | 1.530% | 1.960% | 14.431% | -73.487% | -61.706% | -69.529% | -96.007% |
| Rhythm Pharmaceuticals | -1.080% | 3.315% | -2.604% | 28.082% | 0.000% | 491.772% | 495.541% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-30
General Impression
The financials of Novavax, a Biotechnology & Medical Research company with US symbol NVAX, paint a mixed picture. Over the past few years, the company has reported a significant increase in its revenue and total assets. However, its net income has consistently been in the negative, and it has faced challenges in maintaining a positive net working capital and managing its liabilities.
Detailed Analysis
Comments
Novavax (NVAX) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
Show more
Ratings data for NVAX provided by MarketBeat
Novavax (NVAX) had its "buy" rating reaffirmed by B. Riley Financial, Inc..
Show more
Ratings data for NVAX provided by MarketBeat
Novavax (NVAX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Show more
Ratings data for NVAX provided by MarketBeat
News
Biotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone?
Given that we are barely five years removed from the COVID-19 pandemic, it's natural for consumers and investors to have concerns when hearing about the limited hantavirus outbreak and react
